134 related articles for article (PubMed ID: 4077932)
1. Suramin binds to platelet-derived growth factor and inhibits its biological activity.
Hosang M
J Cell Biochem; 1985; 29(3):265-73. PubMed ID: 4077932
[TBL] [Abstract][Full Text] [Related]
2. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
Huang JS; Nishimura J; Huang SS; Deuel TF
J Cell Biochem; 1984; 26(4):205-20. PubMed ID: 6099364
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
Major TC; Keiser JA
J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
[TBL] [Abstract][Full Text] [Related]
4. Suramin interrupts androgen-inducible autocrine loop involving heparin binding growth factor in mouse mammary cancer (Shionogi carcinoma 115) cells.
Kasayama S; Saito H; Kouhara H; Sumitani S; Sato B
J Cell Physiol; 1993 Feb; 154(2):254-61. PubMed ID: 7678839
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor labeled to colloidal gold for use as a mitogenic receptor probe.
Handley DA; Witte LD
Eur J Cell Biol; 1984 Jul; 34(2):281-6. PubMed ID: 6090144
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
[TBL] [Abstract][Full Text] [Related]
7. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells.
Coffey RJ; Leof EB; Shipley GD; Moses HL
J Cell Physiol; 1987 Jul; 132(1):143-8. PubMed ID: 3496343
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop.
Schrell UM; Gauer S; Kiesewetter F; Bickel A; Hren J; Adams EF; Fahlbusch R
J Neurosurg; 1995 Apr; 82(4):600-7. PubMed ID: 7897522
[TBL] [Abstract][Full Text] [Related]
9. DNA synthesis in U-2 OS human osteosarcoma cells is independent of PDGF binding to functional cell surface receptors.
Richter MR; Graves DT
J Cell Physiol; 1988 Jun; 135(3):474-80. PubMed ID: 2840434
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms through which gangliosides inhibit PDGF-stimulated mitogenesis in intact Swiss 3T3 cells: receptor tyrosine phosphorylation, intracellular calcium, and receptor binding.
Yates AJ; VanBrocklyn J; Saqr HE; Guan Z; Stokes BT; O'Dorisio MS
Exp Cell Res; 1993 Jan; 204(1):38-45. PubMed ID: 8416794
[TBL] [Abstract][Full Text] [Related]
11. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells.
Di Paolo S; Gesualdo L; Ranieri E; Grandaliano G; Schena FP
Am J Pathol; 1996 Dec; 149(6):2095-106. PubMed ID: 8952542
[TBL] [Abstract][Full Text] [Related]
12. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
Kovalenko M; Gazit A; Böhmer A; Rorsman C; Rönnstrand L; Heldin CH; Waltenberger J; Böhmer FD; Levitzki A
Cancer Res; 1994 Dec; 54(23):6106-14. PubMed ID: 7954456
[TBL] [Abstract][Full Text] [Related]
13. Evidence for functional platelet-derived growth factor receptors on MG-63 human osteosarcoma cells.
Graves DT; Antoniades HN; Williams SR; Owen AJ
Cancer Res; 1984 Jul; 44(7):2966-70. PubMed ID: 6327031
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells.
Vlahos CJ; Kriauciunas TD; Gleason PE; Jones JA; Eble JN; Salvas D; Falcone JF; Hirsch KS
J Cell Biochem; 1993 Aug; 52(4):404-13. PubMed ID: 7693727
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of 125I-PDGF binding and down-regulation of PDGF receptor in arterial smooth muscle cells derived from patients with moyamoya disease.
Aoyagi M; Fukai N; Matsushima Y; Yamamoto M; Yamamoto K
J Cell Physiol; 1993 Feb; 154(2):281-8. PubMed ID: 8425908
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth factor binding, Ca2+ signaling and cell growth by polysulfonated azo dyes related to the antitumor agent suramin.
Powis G; Seewald MJ; Melder D; Hoke M; Gratas C; Christensen TA; Chapman DE
Cancer Chemother Pharmacol; 1992; 31(3):223-8. PubMed ID: 1464160
[TBL] [Abstract][Full Text] [Related]
17. CDGF (chicken embryo fibroblast-derived growth factor) is mitogenically related to TGF-beta and modulates PDGF, bFGF, and IGF-I action on sparse NIH/3T3 cells.
Geistlich A; Gehring H
Exp Cell Res; 1993 Feb; 204(2):329-35. PubMed ID: 8440329
[TBL] [Abstract][Full Text] [Related]
18. Density-dependent inhibitory effect of transforming growth factor-beta 1 on human fibroblasts involves the down-regulation of platelet-derived growth factor alpha-receptors.
Paulsson Y; Karlsson C; Heldin CH; Westermark B
J Cell Physiol; 1993 Oct; 157(1):97-103. PubMed ID: 8408247
[TBL] [Abstract][Full Text] [Related]
19. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression.
Mills GB; Zhang N; May C; Hill M; Chung A
Cancer Res; 1990 May; 50(10):3036-42. PubMed ID: 1692253
[TBL] [Abstract][Full Text] [Related]
20. Influence of suramin alone or in combination with DHT and PDGF on the cell proliferation of benign and malignant human prostatic tissues in organ cultures.
Michel P; Van Velthoven R; Petein M; Gras S; Etievant C; Pasteels JL; Kiss R
Anticancer Res; 1991; 11(6):2075-8. PubMed ID: 1723262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
